FMO5 and prostate cancer: However, modulating prostate cancer cell redox states with parthenolide, a sesquiterpene lactone, potentiates radiotherapy-mediated cell toxicity by diminishing anti-oxidant defense via NADPH oxidase-dependent ROS generation and activation of the PI3K/AKT/FOXO signaling pathway [125].